CATALYST PHARMACEUTICA

NetDania - New 12 months High: CATALYST PHARMACEUTICALS INC. - COMMON STOCK

13 Aug 2024 08:45:04 By NetDania Notify

NetDania - New 12 months High: CATALYST PHARMACEUTICALS INC. - COMMON STOCK

12 Aug 2024 14:05:33 By NetDania Notify

NetDania - New 12 months High: CATALYST PHARMACEUTICALS INC. - COMMON STOCK

09 Aug 2024 09:22:00 By NetDania Notify

NetDania - New 12 months High: CATALYST PHARMACEUTICALS INC. - COMMON STOCK

08 Aug 2024 11:28:33 By NetDania Notify

Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update

07 Aug 2024 15:11:34 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CATALYST PHARMACEUTICALS INC. - COMMON STOCK

24 Jul 2024 08:55:10 By NetDania Notify

Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada

24 Jul 2024 07:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CATALYST PHARMACEUTICALS INC. - COMMON STOCK

23 Jul 2024 09:55:07 By NetDania Notify

Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024

22 Jul 2024 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®

30 May 2024 12:41:21 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024

28 May 2024 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update

08 May 2024 15:16:20 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024

01 May 2024 07:00:01 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024

22 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day

28 Mar 2024 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

27 Mar 2024 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

13 Mar 2024 06:55:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

05 Mar 2024 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

28 Feb 2024 17:03:23 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE

27 Feb 2024 07:03:00 By Nasdaq GlobeNewswire